The software package, East, is currently used across the industry for the design of adaptive and innovative clinical trials through licensed subscriptions.
With the launch of East On Demand, the software’s features will be available to companies that require shorter or less frequent use of the system, as it will now be available 24/7 through the cloud with options for more flexible subscriptions.
Anne Pelz, VP of product management at Cytel, explained that small biotech companies face challenges during the clinical development process, often working with small budgets and limited IT infrastructure for software environments.
Pelz added that these companies are among those which would benefit most from an optimized adaptive trial design approach, because these methodologies enable the generation of data from small patient groups while reducing the development costs and trial failure risk.
Additionally, Cytel will launch its StatXact 12 and LogXact 12, which further build on the tests and procedures for exact inference, power analysis, and regression analysis available in the StatXact and LogXact software packages.
“Cytel has thus ensured that East On Demand offers a holistic solution for the smaller biotech, delivering the full arsenal of adaptive design tools in a way that is optimally accessible for them,” Pelz stated.
According to Cytel, the addition of features in StatXact 12 and LogXact 12, such as the saddlepoint approximation method and multiple endpoints procedure with gatekeeping, can provide solutions to computational challenges that may arise during trial design. By supporting the transition to the lasts version of SAS, StatXact 12 and LogXact 12 also enable companies to keep current with security standards and system suitability requirements and comply with US Food and Drug Administration (FDA) guidances.